Vir Biotechnology Inc
VIR6.110USD
+0.120+2.00%
Close 12/24, 13:00（ET）Quotes delayed by 15 min
849.43MMarket Cap
LossP/E TTM
More Details of Vir Biotechnology Inc Company
Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Its clinical-stage portfolio includes infectious disease programs for chronic hepatitis delta and chronic hepatitis B infections and multiple dual-masked T-cell engagers across validated targets in solid tumor indications. It also has a preclinical portfolio of programs across a range of infectious diseases and oncologic malignancies. Tobevibart is an investigational neutralizing monoclonal antibody (mAb) that has been engineered for immune engagement and targets a conserved region on the hepatitis B surface antigen (HBsAg). Elebsiran is an investigational HBV-targeted small interfering RNA (siRNA) that reduces HBsAg. Its pipeline includes VIR-5818, VIR-5500, VIR-5525, and HIV Cure. It also has rights to the PRO-XTEN masking platform for oncology and infectious disease.
Vir Biotechnology Inc Info
Ticker SymbolVIR
Company nameVir Biotechnology Inc
IPO dateOct 11, 2019
CEODe Backer (Marianne)
Number of employees408
Security typeOrdinary Share
Fiscal year-endOct 11
Address1800 Owens Street
CitySAN FRANCISCO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94158
Phone14159064324
Websitehttps://www.vir.bio/
Ticker SymbolVIR
IPO dateOct 11, 2019
CEODe Backer (Marianne)
Company Executives of Vir Biotechnology Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Robert J. (Bob) More
Mr. Robert J. (Bob) More
Independent Director
Independent Director
32.66K
-30.05%
Mr. Jeffrey S. (Jeff) Hatfield
Mr. Jeffrey S. (Jeff) Hatfield
Independent Director
Independent Director
23.81K
+50.61%
Dr. Marianne De Backer, Ph.D.
Dr. Marianne De Backer, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
19.03K
-80.53%
Ms. Saira Ramasastry
Ms. Saira Ramasastry
Independent Director
Independent Director
14.62K
+120.86%
Dr. Norbert W. Bischofberger, Ph.D.
Dr. Norbert W. Bischofberger, Ph.D.
Independent Director
Independent Director
8.00K
--
Ms. Vanina De Verneuil, J.D.
Ms. Vanina De Verneuil, J.D.
Executive Vice President, General Counsel, Corporate Secretary
Executive Vice President, General Counsel, Corporate Secretary
936.00
-80.03%
Dr. Mark Eisner, M.D.
Dr. Mark Eisner, M.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
--
--
Ms. Janet Napolitano, J.D.
Ms. Janet Napolitano, J.D.
Independent Director
Independent Director
--
--
Mr. Jason V. O'byrne
Mr. Jason V. O'byrne
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
Dr. Vicki L. Sato, Ph.D.
Dr. Vicki L. Sato, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Robert J. (Bob) More
Mr. Robert J. (Bob) More
Independent Director
Independent Director
32.66K
-30.05%
Mr. Jeffrey S. (Jeff) Hatfield
Mr. Jeffrey S. (Jeff) Hatfield
Independent Director
Independent Director
23.81K
+50.61%
Dr. Marianne De Backer, Ph.D.
Dr. Marianne De Backer, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
19.03K
-80.53%
Ms. Saira Ramasastry
Ms. Saira Ramasastry
Independent Director
Independent Director
14.62K
+120.86%
Dr. Norbert W. Bischofberger, Ph.D.
Dr. Norbert W. Bischofberger, Ph.D.
Independent Director
Independent Director
8.00K
--
Ms. Vanina De Verneuil, J.D.
Ms. Vanina De Verneuil, J.D.
Executive Vice President, General Counsel, Corporate Secretary
Executive Vice President, General Counsel, Corporate Secretary
936.00
-80.03%
Revenue Breakdown
FY2024
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
74.20M
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
SB Investment Advisers (UK) Limited
10.26%
BlackRock Institutional Trust Company, N.A.
9.86%
ARCH Venture Partners
9.28%
The Vanguard Group, Inc.
9.18%
GSK plc
6.15%
Other
55.27%
Shareholders
Shareholders
Proportion
SB Investment Advisers (UK) Limited
10.26%
BlackRock Institutional Trust Company, N.A.
9.86%
ARCH Venture Partners
9.28%
The Vanguard Group, Inc.
9.18%
GSK plc
6.15%
Other
55.27%
Shareholder Types
Shareholders
Proportion
Investment Advisor
29.37%
Investment Advisor/Hedge Fund
15.11%
Private Equity
11.97%
Venture Capital
9.75%
Corporation
6.15%
Hedge Fund
6.07%
Individual Investor
4.27%
Research Firm
3.10%
Foundation
1.12%
Other
13.09%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
481
113.05M
81.28%
-6.82M
2025Q2
530
124.85M
89.88%
-15.28M
2025Q1
571
125.80M
91.30%
-16.44M
2024Q4
568
122.14M
89.06%
-13.83M
2024Q3
554
118.76M
86.83%
-17.44M
2024Q2
572
119.53M
87.47%
-20.55M
2024Q1
564
122.68M
91.07%
-16.10M
2023Q4
577
121.87M
90.75%
-16.40M
2023Q3
578
123.93M
92.29%
-3.81M
2023Q2
574
125.10M
93.31%
+332.42K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
SB Investment Advisers (UK) Limited
16.68M
12.01%
--
--
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
13.85M
9.97%
-523.21K
-3.64%
Jun 30, 2025
ARCH Venture Partners
12.92M
9.3%
--
--
Jun 30, 2025
The Vanguard Group, Inc.
13.20M
9.5%
+419.56K
+3.28%
Jun 30, 2025
GSK plc
8.55M
6.16%
--
--
Apr 01, 2025
State Street Investment Management (US)
5.25M
3.78%
-472.45K
-8.25%
Jun 30, 2025
Scangos (George A)
3.78M
2.72%
-550.77K
-12.72%
Apr 01, 2025
Dimensional Fund Advisors, L.P.
3.01M
2.17%
+323.54K
+12.05%
Jun 30, 2025
Fidelity Institutional Asset Management
2.60M
1.87%
+2.17M
+508.24%
Jun 30, 2025
OrbiMed Advisors, LLC
2.38M
1.71%
+132.47K
+5.89%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Genomics Immunology and Healthcare ETF
1.13%
Virtus LifeSci Biotech Clinical Trials ETF
0.77%
Invesco NASDAQ Future Gen 200 ETF
0.65%
Global X Genomics & Biotechnology ETF
0.59%
Invesco S&P SmallCap Health Care ETF
0.34%
ALPS Medical Breakthroughs ETF
0.34%
Hypatia Women CEO ETF
0.27%
State Street SPDR S&P Biotech ETF
0.2%
ProShares Ultra Nasdaq Biotechnology
0.11%
Direxion Daily S&P Biotech Bull 3X Shares
0.1%
View more
iShares Genomics Immunology and Healthcare ETF
Proportion1.13%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0.77%
Invesco NASDAQ Future Gen 200 ETF
Proportion0.65%
Global X Genomics & Biotechnology ETF
Proportion0.59%
Invesco S&P SmallCap Health Care ETF
Proportion0.34%
ALPS Medical Breakthroughs ETF
Proportion0.34%
Hypatia Women CEO ETF
Proportion0.27%
State Street SPDR S&P Biotech ETF
Proportion0.2%
ProShares Ultra Nasdaq Biotechnology
Proportion0.11%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.1%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Vir Biotechnology Inc?
The top five shareholders of Vir Biotechnology Inc are:
SB Investment Advisers (UK) Limited holds 16.68M shares, accounting for 12.01% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 13.85M shares, accounting for 9.97% of the total shares.
ARCH Venture Partners holds 12.92M shares, accounting for 9.30% of the total shares.
The Vanguard Group, Inc. holds 13.20M shares, accounting for 9.50% of the total shares.
GSK plc holds 8.55M shares, accounting for 6.16% of the total shares.
SB Investment Advisers (UK) Limited holds 16.68M shares, accounting for 12.01% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 13.85M shares, accounting for 9.97% of the total shares.
ARCH Venture Partners holds 12.92M shares, accounting for 9.30% of the total shares.
The Vanguard Group, Inc. holds 13.20M shares, accounting for 9.50% of the total shares.
GSK plc holds 8.55M shares, accounting for 6.16% of the total shares.
What are the top three shareholder types of Vir Biotechnology Inc?
The top three shareholder types of Vir Biotechnology Inc are:
SB Investment Advisers (UK) Limited
BlackRock Institutional Trust Company, N.A.
ARCH Venture Partners
SB Investment Advisers (UK) Limited
BlackRock Institutional Trust Company, N.A.
ARCH Venture Partners
How many institutions hold shares of Vir Biotechnology Inc (VIR)?
As of 2025Q3, 481 institutions hold shares of Vir Biotechnology Inc, with a combined market value of approximately 113.05M, accounting for 81.28% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -8.60%.
What is the biggest source of revenue for Vir Biotechnology Inc?
In FY2024, the -- business generated the highest revenue for Vir Biotechnology Inc, amounting to -- and accounting for --% of total revenue.
